Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival

por Fromigue, O, Kheddoumi, N, Body, J-J
Publicado 2003

Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.

por Body, J. J., Dumon, J. C., Gineyts, E., Delmas, P. D.
Publicado 1997

Gorham–Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid

por Yerganyan, V.V., Body, J.J., De Saint Aubain, N., Gebhart, M.
Publicado 2015

Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells

por Absil, L., Journé, F., Larsimont, D., Body, J. J., Tafforeau, L., Nonclercq, D.
Publicado 2020

Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells

por Journe, F, Chaboteaux, C, Dumon, J-C, Leclercq, G, Laurent, G, Body, J-J
Publicado 2004

Increased Dickkopf-1 expression in breast cancer bone metastases

por Voorzanger-Rousselot, N, Goehrig, D, Journe, F, Doriath, V, Body, J J, Clézardin, P, Garnero, P
Publicado 2007

What is the validity of self-reported fractures?

por Baleanu, F., Moreau, M., Kinnard, V., Iconaru, L., Karmali, R., Paesmans, M., Bergmann, P., Body, J.J.
Publicado 2020

The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohort

por Iconaru, L., Charles, A., Baleanu, F., Moreau, M., Surquin, M., Benoit, F., Body, J.J., Bergmann, P.
Publicado 2023

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studie...

por Body, J J, Diel, I J, Lichinitzer, M, Lazarev, A, Pecherstorfer, M, Bell, R, Tripathy, D, Bergstrom, B
Publicado 2004

Loading and Skeletal Development and Maintenance

por Bergmann, P., Body, J. J., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Kaufman, J., Reginster, J. Y., Rozenberg, S.
Publicado 2010

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

por Body, J.-J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Rozenberg, S., Reginster, J.-Y.
Publicado 2010

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications

por Body, J.-J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J.-M., Rozenberg, S., Reginster, J.-Y.
Publicado 2012

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of t...

por Bergmann, P, Body, J-J, Boonen, S, Boutsen, Y, Devogelaer, J-P, Goemaere, S, Kaufman, J-M, Reginster, J-Y, Gangji, V
Publicado 2009

Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club

por Body, J.-J., Bergmann, P., Boonen, S., Boutsen, Y., Bruyere, O., Devogelaer, J.-P., Goemaere, S., Hollevoet, N., Kaufman, J.-M., Milisen, K., Rozenberg, S., Reginster, J.-Y.
Publicado 2011

Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club

por Gielen, E., Bergmann, P., Bruyère, O., Cavalier, E., Delanaye, P., Goemaere, S., Kaufman, J.-M., Locquet, M., Reginster, J.-Y., Rozenberg, S., Vandenbroucke, A.-M., Body, J.-J.
Publicado 2017

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

por Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E. U., Thürlimann, B., Walls, J., Lichinitser, M. R., Rizzoll, R., Hagberg, H., Huss, H. J., Tubiana-Hulin, M., Body, J. J.
Publicado 1997

Efficacy of teriparatide compared with risedronate on FRAX(®)-defined major osteoporotic fractures: results of the VERO clinical trial

por Body, J.-J., Marin, F., Kendler, D.L., Zerbini, C.A.F., López-Romero, P., Möricke, R., Casado, E., Fahrleitner-Pammer, A., Stepan, J.J., Lespessailles, E., Minisola, S., Geusens, P.
Publicado 2020

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

por Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
Publicado 2012

Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

por Kendler, D.L., Body, J.J., Brandi, M.L., Broady, R., Cannata-Andia, J., Cannata-Ortiz, M.J., El Maghraoui, A., Guglielmi, G., Hadji, P., Pierroz, D.D., de Villiers, T.J., Ebeling, P.R., Rizzoli, R.
Publicado 2021